Probiotic trial reported immune-marker changes; clinical benefits were not reported in the abstract
A small human trial within a broader safety study described changes in blood immune markers and gut microbes, without reporting effects on illness.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
After daily intake of the tested probiotic strain, the human trial reported increases in an antimicrobial peptide and several antibodies. Gut microbial features also changed, while a diversity measure showed no statistically significant change. These are laboratory outcomes; the abstract does not report whether participants had fewer infections, felt better, or experienced other clinical benefits.
The comparator and reference for the percentage changes are unclear. Human adverse-event results are not supplied, and laboratory or mouse findings do not establish safety across human populations. This account is based on the abstract.
What the human trial examined
Participants consumed Limosilactobacillus fermentum LF61, a strain obtained from human milk. Researchers measured blood immune markers and examined gut microbial features, including bacterial groups and a pathway involved in carbohydrate metabolism.
What the safety tests covered
Genetic screening reported no virulence factors, drug resistance genes, or toxin gene clusters. Cell experiments and an acute mouse toxicity test provided additional safety information. The abstract does not establish long-term human tolerability.
The original publication
Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application.
Jin M, Xu F, Liu Y et al.
Food Chem Toxicol · 2026
- PubMed ID
- 41655688
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.